270 related articles for article (PubMed ID: 22228505)
1. Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia.
Farris M; Lague A; Manuelyan Z; Statnekov J; Francklyn C
Proteins; 2012 Apr; 80(4):1095-109. PubMed ID: 22228505
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
3. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
4. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
[TBL] [Abstract][Full Text] [Related]
5. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
[TBL] [Abstract][Full Text] [Related]
6. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
7. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
[TBL] [Abstract][Full Text] [Related]
8. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
9. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
[TBL] [Abstract][Full Text] [Related]
10. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
11. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
12. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
13. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
14. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
15. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
16. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance.
Zayed A; Couban S; Hayne O; Sparavalo N; Shawwa A; Sadek I; Greer W
Leuk Lymphoma; 2007 Mar; 48(3):489-96. PubMed ID: 17454588
[TBL] [Abstract][Full Text] [Related]
18. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia.
Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T
Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.
McNamara S; Wang H; Hanna N; Miller WH
Mol Cell Biol; 2008 Mar; 28(6):2066-77. PubMed ID: 18212063
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
